Stay updated on Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial

Sign up to get notified when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer now displays website revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-11-01T15:52:53.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    A site-wide NIH announcement has been added above the study record, describing a transition from the term “Artificial Intelligence” to “Super Intelligence.”
    Difference
    0.5%
    Check dated 2026-10-25T16:52:22.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-18T19:00:07.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The site footer now displays release revision v3.7.1 instead of v3.7.0; the study record content is unchanged.
    Difference
    0.1%
    Check dated 2026-10-11T19:45:01.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    A new revision entry, v3.7.0, was added to the Record History and the previous v3.6.6 entry was removed. This reflects an update to the page's version history.
    Difference
    0.1%
    Check dated 2026-09-20T20:41:54.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    - The record history now includes a new Revision: v3.6.6, replacing the previous Revision: v3.6.5. This indicates an update to the page's revision history metadata.
    Difference
    0.1%
    Check dated 2026-08-30T06:20:25.000Z thumbnail image

Stay in the know with updates to Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.